cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1494Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMПульс-урежающие антиангинальные препараты: что определяет их выбор?Heart rate-lowering antianginal medications: what determines their choice?ЛопатинЮ. М.LopatinYu. M.lopatin@vlpost.ruВолгоградский государственный медицинский университет; Волгоградский областной кардиологический центр, ВолгоградVolgograd State Medical University, Volgograd Regional Cardiology Center, Volgograd200701011970778489Copyright © Лопатин Ю.М., 19701970Лопатин Ю.М.Lopatin Y.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1494

Статья посвящена выбору пульс-урежающих антиангинальных препаратов для лечения больных стабильной стенокардией. Проанализирован алгоритм антиангинальной терапии, предложенный Европейским Обществом Кардиологов (2006).

The article is focused on choosing heart rate-lowering antianginal medications for patients with stable angina. Antianginal therapy algorithm by the European Society of Cardiology (2006) is analyzed.

стабильная стенокардиябета-блокаторыантагонисты кальцияингибитор If каналов ивабрадинStable anginabeta-blockerscalcium antagonistsIf channel inhibitor ivabradineReferencesДиагностика и лечение стабильной стенокардии. Российские рекомендации, 2004.Диагностика и лечение стабильной стенокардии. Российские рекомендации, 2004.Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.Freemantle N, Cleland J, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. Br Med J 1999; 318: 1730–7.Freemantle N, Cleland J, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. Br Med J 1999; 318: 1730–7.The Danish Verapamil Infarction Trial II – DAVIT II. Effect of verapamil on mortality and major events after myocardial infarction. Am J Cardiol 1990; 66: 779–85.The Danish Verapamil Infarction Trial II – DAVIT II. Effect of verapamil on mortality and major events after myocardial infarction. Am J Cardiol 1990; 66: 779–85.The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92.The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92.Boden WE, van Gilst WY, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: A randomized placebo-controlled trial. Lancet 2000; 355: 1751–6.Boden WE, van Gilst WY, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: A randomized placebo-controlled trial. Lancet 2000; 355: 1751–6.Bangalore S, Messerli FH, Cohen JD, et al. Verapamil-SR strategy is comparable to atenolol strategy at reducing cardiovascular events in patients with prior myocardial infarction: an International Verapamil SR-Trandolapril (INVEST) substudy. JACC 2007; 49(Suppl. A): 232A.Bangalore S, Messerli FH, Cohen JD, et al. Verapamil-SR strategy is comparable to atenolol strategy at reducing cardiovascular events in patients with prior myocardial infarction: an International Verapamil SR-Trandolapril (INVEST) substudy. JACC 2007; 49(Suppl. A): 232A.Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trial comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 1927–36.Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trial comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 1927–36.Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76–81.Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J 1996; 17: 76–81.Gibbson RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 1999; 33: 2092–197.Gibbson RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 1999; 33: 2092–197.Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers. A critical review of the evidence. JACC 2007; 50: 563–72.Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers. A critical review of the evidence. JACC 2007; 50: 563–72.Tendera M. What can If inhibition contributes to the treatment of left ventricular dysfunction? Medicographia 2006; 28: 275–7.Tendera M. What can If inhibition contributes to the treatment of left ventricular dysfunction? Medicographia 2006; 28: 275–7.Expert consensus document on β-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of cardiology. Eur Heart J 2004; 25: 1341–62.Expert consensus document on β-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of cardiology. Eur Heart J 2004; 25: 1341–62.Purcell Y, Fox K. Selective and specific If inhibition: new perspectives. Medicographia 2005; 27: 51–5Purcell Y, Fox K. Selective and specific If inhibition: new perspectives. Medicographia 2005; 27: 51–5Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blokers, angiotensin-converting enzyme inhibitors, and statins after myocardial infarction. Eur Heart J 2006; 27: 1153–8.Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blokers, angiotensin-converting enzyme inhibitors, and statins after myocardial infarction. Eur Heart J 2006; 27: 1153–8.Daly CA, Clements F, Lopez Sendoz JL, et al. The initial management of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005; 26: 1011–22.Daly CA, Clements F, Lopez Sendoz JL, et al. The initial management of stable angina in Europe, from the Euro Heart Survey. Eur Heart J 2005; 26: 1011–22.Daly CA, Clements F, Lopez Sendoz JL, et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006; 27: 1298–304.Daly CA, Clements F, Lopez Sendoz JL, et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J 2006; 27: 1298–304.Vliegen HW, van der Wall EE, Niemeyer MG, et al. Long-term efficacy of diltiazem controlled release versus metoprolol in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991; 18(Suppl. 9): S55–60.Vliegen HW, van der Wall EE, Niemeyer MG, et al. Long-term efficacy of diltiazem controlled release versus metoprolol in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991; 18(Suppl. 9): S55–60.Tardif J-C, Fox K, Tendera M, et al. Absence of rebound phenomenon after abrupt discontinuation of ivabradine, a new selective and specific If inhibitor, in patients with coronary artery disease. Eur Heart J 2005; 26: 580 (abstract P3496).Tardif J-C, Fox K, Tendera M, et al. Absence of rebound phenomenon after abrupt discontinuation of ivabradine, a new selective and specific If inhibitor, in patients with coronary artery disease. Eur Heart J 2005; 26: 580 (abstract P3496).Tardif J-C, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heat J 2005; 26: 2529–36.Tardif J-C, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heat J 2005; 26: 2529–36.

The authors declare that there are no conflicts of interest present.